# VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

> clinical trial · VERIFIED · 2026-07-15

Status: RECRUITING · Sponsor: Replimune, Inc. · Condition: Advanced Melanoma

- Company: Replimune, Inc.
- Sector: Advanced Melanoma
- Primary source: https://clinicaltrials.gov/study/NCT06264180

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.